Athira Pharma
ATHA

$3.31

0.3%

Market Cap: 127M

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Employees: 67

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

126% more call options, than puts

Call options by funds: $269K | Put options by funds: $119K

17% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 18

16% more funds holding

Funds holding: 64 [Q4 2023] → 74 (+10) [Q1 2024]

12% more capital invested

Capital invested by funds: $53.2M [Q4 2023] → $59.4M (+$6.24M) [Q1 2024]

0.92% less ownership

Funds ownership: 57.51% [Q4 2023] → 56.59% (-0.92%) [Q1 2024]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$19

474%

upside

Avg. target

$19

474%

upside

High target

$19

474%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jason Butler	474%upside $19	Market Outperform Reiterated	20 Jun 2024
JMP Securities Jason Butler	474%upside $19	Market Outperform Reiterated	16 May 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)

SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al.

Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)

Athira Pharma to Participate in Upcoming June Conferences

Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al., No. 2:22-cv-497 and Houlihan v. Kawas et al., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., May 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma to Participate in Upcoming May Conferences

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D.

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer's disease.

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

See News Rankings